02 Sep CJC-1295 DAC: Understanding the 2 mg Tetrasubstituted 30-Amino Acid Peptide Hormone by Deus Medical
CJC-1295 DAC, a synthetic peptide that stimulates the release of growth hormone, has gained significant attention in the field of medical research and bodybuilding. This tetrasubstituted peptide hormone consists of 30 amino acids and provides unique properties that set it apart from other growth hormone-releasing peptides.
What is CJC-1295 DAC?
CJC-1295 DAC is a more stable form of growth hormone-releasing hormone (GHRH). The “DAC” in its name stands for Drug Affinity Complex, indicating its enhanced half-life in the bloodstream due to the incorporation of drug affinity technology. This stability allows for less frequent dosing and sustained release of growth hormone, making it a preferred choice among athletes and individuals looking to increase muscle mass and improve recovery.
Benefits of CJC-1295 DAC
- Increased Growth Hormone Release: Promotes the natural secretion of growth hormone, leading to improved muscle growth and fat loss.
- Enhanced Recovery: Speeds up healing processes and reduces recovery time after workouts or injuries.
- Improved Sleep Quality: Has been reported to enhance deep sleep, which is crucial for recovery and overall health.
- Potential Anti-Aging Effects: May help mitigate some age-related declines in muscle mass and overall vitality.
Dosage and Administration
The typical dosage for CJC-1295 DAC is around 2 mg, which can be administered subcutaneously. As with any peptide, it’s essential to follow a healthcare provider’s instructions to ensure safety and efficiency in usage.
Conclusion
CJC-1295 DAC stands out as a beneficial peptide for those seeking to enhance their physical performance and recovery. Its ability to stimulate growth hormone release in a sustained manner presents a promising option for athletes and enthusiasts alike. However, it’s crucial to undertake any supplementation under medical supervision to maximize benefits and mitigate potential side effects.

Sorry, the comment form is closed at this time.